Amanda Noska1, Aron Mohan2, Sarah Wakeman3, Josiah Rich1, Amy Boutwell4. 1. Brown University and Warren Alpert Medical School, Providence, RI, USA ; Lifespan Corporation, Rhode Island Hospital and The Miriam Hospital, Providence, RI, USA. 2. Brown University and Warren Alpert Medical School, Providence, RI, USA. 3. Massachusetts General Hospital, Department of Medicine, Boston, MA, USA ; Harvard Medical School, Boston, MA, USA. 4. Massachusetts General Hospital, Department of Medicine, Boston, MA, USA ; Harvard Medical School, Boston, MA, USA ; Collaborative Healthcare Strategies, Lexington, MA, USA.
Abstract
OBJECTIVE: Treatment with an opioid agonist such as methadone or buprenorphine is the standard of care for opioid use disorder. Persons with opioid use disorder are frequently hospitalized, and may be undertreated due to provider misinformation regarding the legality of prescribing methadone for inpatients. Using a case-based review, this article aims to describe effective management of active opioid withdrawal and ongoing opioid use disorder using methadone or buprenorphine among acutely ill, hospitalized patients. METHODS: We reviewed pertinent medical and legal literature and consulted with national legal experts regarding methadone for opioid withdrawal and opioid maintenance therapy in hospitalized, general medical and surgical patients, and describe a real-life example of successful implementation of inpatient methadone for these purposes. RESULTS: Patients with opioid use disorders can be effectively and legally initiated on methadone maintenance therapy or buprenorphine during an inpatient hospitalization by clinical providers and successfully transitioned to an outpatient methadone maintenance or buprenorphine clinic after discharge for ongoing treatment. CONCLUSIONS: Inpatient methadone or buprenorphine prescribing is safe and evidence-based, and can be used to effectively treat opioid withdrawal and also serves as a bridge to outpatient treatment of opioid use disorders.
OBJECTIVE: Treatment with an opioid agonist such as methadone or buprenorphine is the standard of care for opioid use disorder. Persons with opioid use disorder are frequently hospitalized, and may be undertreated due to provider misinformation regarding the legality of prescribing methadone for inpatients. Using a case-based review, this article aims to describe effective management of active opioid withdrawal and ongoing opioid use disorder using methadone or buprenorphine among acutely ill, hospitalized patients. METHODS: We reviewed pertinent medical and legal literature and consulted with national legal experts regarding methadone for opioid withdrawal and opioid maintenance therapy in hospitalized, general medical and surgical patients, and describe a real-life example of successful implementation of inpatient methadone for these purposes. RESULTS:Patients with opioid use disorders can be effectively and legally initiated on methadone maintenance therapy or buprenorphine during an inpatient hospitalization by clinical providers and successfully transitioned to an outpatientmethadone maintenance or buprenorphine clinic after discharge for ongoing treatment. CONCLUSIONS: Inpatient methadone or buprenorphine prescribing is safe and evidence-based, and can be used to effectively treat opioid withdrawal and also serves as a bridge to outpatient treatment of opioid use disorders.
Authors: Alan G White; Howard G Birnbaum; Milena N Mareva; Maham Daher; Susan Vallow; Jeff Schein; Nathaniel Katz Journal: J Manag Care Pharm Date: 2005 Jul-Aug
Authors: Thomas Kerr; Nadia Fairbairn; Mark Tyndall; David Marsh; Kathy Li; Julio Montaner; Evan Wood Journal: Drug Alcohol Depend Date: 2006-09-07 Impact factor: 4.492
Authors: Robert P Schwartz; Jan Gryczynski; Kevin E O'Grady; Joshua M Sharfstein; Gregory Warren; Yngvild Olsen; Shannon G Mitchell; Jerome H Jaffe Journal: Am J Public Health Date: 2013-03-14 Impact factor: 9.308
Authors: Elizabeth L C Merrall; Azar Kariminia; Ingrid A Binswanger; Michael S Hobbs; Michael Farrell; John Marsden; Sharon J Hutchinson; Sheila M Bird Journal: Addiction Date: 2010-06-23 Impact factor: 6.526
Authors: Herbert C Duber; Isabel A Barata; Eric Cioè-Peña; Stephen Y Liang; Eric Ketcham; Wendy Macias-Konstantopoulos; Shawn A Ryan; Mark Stavros; Lauren K Whiteside Journal: Ann Emerg Med Date: 2018-06-05 Impact factor: 5.721
Authors: Zoe M Weinstein; Debbie M Cheng; Maria J D'Amico; Leah S Forman; Danny Regan; Alexandra Yurkovic; Jeffrey H Samet; Alexander Y Walley Journal: Drug Alcohol Depend Date: 2020-05-25 Impact factor: 4.492
Authors: Joji Suzuki; Jennifer Johnson; Mary Montgomery; Margaret Hayden; Christin Price Journal: Open Forum Infect Dis Date: 2018-08-07 Impact factor: 3.835